Business Standard
Sunday, Nov 22, 2009
 
drived banner
drived banner
  Advanced Search
Feedback | RSS
Content Guide
Follow us on  
  Home  |Markets & Investing|Companies & Industry|Banking & Finance|Economy & Policy|Opinion|Life & Leisure|Mgmt & Mktg|Tech World|BS Products 
 BS Headlines | News Now | BS Weekend | The strategist | The Smart Investor | Lunch with BS | Columnists | BS 1000
  Hindi | E-Paper | Motoring  | Live Markets |  Smart Portfolios II  | Blogs | Portfolios >
  Search:
Divi`s Labs: In good health
Shobhana Subramanian & Amriteshwar Mathur / Mumbai June 11, 2008, 4:31 IST
Sales at the Rs 1,033 crore Divi's Laboratories grew 43 per cent in FY 08 though the pace was slower than in the previous year, when they grew at 90 per cent on a much lower base.
 
Both the company's key businesses, generics and custom chemical synthesis (CCS) —- contract manufacturing for drug firms—- found good demand in overseas markets.

As such, exports now constitute about 90 -95 per cent of the company's annual turnover. The business was profitable : the operating profit margin (opm) expanded by 630 basis points to 40.3 per cent, with the company keeping a least on manufacturing costs. As such, the operating profit grew an impressive 69 per cent to Rs 417 crore.

Divi's is possibly one of the top three global generic suppliers of Naproxen (arthritis), Diltiazem (anti-hypertensive) and Dextromethorphan (medication for cough and cold).

Being mature products, prices have stabilised but demand should grow at about 10 per cent annually. The company is understood to be working with several global players for its CCS division but details are not available.
 
The company expects to grow it top line by 25 per cent in FY09 by exploiting opportunities from its recently commissioned carotenoids facility (medication to increase immunity). Divi's is understood to have commenced supplies to its overseas partners and analysts say that they expect a gradual ramp-up in sales over the next two years.
 
The company's net profit was Rs 354 crore in FY 08 and is expected to grow about 30 per cent in FY09 with the earnings per share rising to around Rs 70.
 
The stock closed 4.76 per cent higher at Rs 1,524 on Tuesday just below its 3-month high reached in the first week of June.It trades at 21.5 times estimated FY09 earnings which is much more expensive than Dishman Pharma, which at Rs 309, trades at 16.6 times FY 09 earnings.

 
Arrow Other Stories     
- Sensex makes remarkable recovery, regains 17K
- S C Kalia takes over as Union Bank ED
- PNB may acquire majority stake in Kazakh bank
- Maoist hindering land acquisition for Tata steel project: Raman
- Koda says he will report to ED only after Jharkhand polls
More  
  Read Business news in 
Advertisements
  Get financial advisory and solutions for your projects
  Holidays starting at a delightful EMI of Rs 3481
  Switch on and say hello to Monday morning !
  Your dream home can now be a reality.
  Visit Fortis for a preventive health check-up & get a 20% discount.
  Follow the ups and downs of your investments. Try our new Portfolio Tracker
  Kolkata Dock \ Freight contract for the British Gurkhas Nepal
  Find how Midsize Businesses use ERP to gain competitive advantage
  Trading in Forex is now as easy as 1-2-3
  Discover an economical and cost effective way to market your products and services
  Giftwithlove.com: Same day delivery of Flowers and Cakes to India
  Download the E-book on the Future of Business Intelligence
  Learn Best Practices for improving customer satisfaction
  Know your customers better... download the free e-book on CRM
   Discussion Board / User Comments    
Display Name  Email-Id  
Post your comment
Most Popular
Read
E-Mailed
Commented
   
- Kurbaan could be Karan Johar's first flop
- A golden lining seen in silver prices
- CBI arrests one more in Satyam fraud case
- Ambani Jr, Brad Pitt join hands for sci-fi film
- Now, Sebi on MNS radar
 
 More  
BS Poll
Cast Your Vote
 
   
 
Should India's defence sector be thrown open to foreign investments?
  Yes  No
Submit

  Hot Searches  
 
Amitabh Bachchan | N Chandrasekaran | Swine Flu | Mukesh Ambani | Anil Ambani | TCS | Infosys |  Air India |  Duronto |  Pranab Mukherjee | Sonia Gandhi | Congress | Rahul Gandhi |  Bigg Boss |  New Pension Scheme |  Service tax |  Excise duty |  Sebi | Tech Mahindra |  Ramalinga Raju |  Satyam |  Reliance  |  RBI |  GDP |  Gold |  Ratan Tata |  ICICI |  |  B-School | DLF  Sensex |  Tax calculator | Home Loan  | Bollywood | Personal Finance |  inflation | oil prices |  World Bank | Reliance Infratel |  HDFC |  Barack Obama  
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring
FOR HOT PRODUCTS
BS Bazaar.com
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Site Map | Contact Us | Feedback